AC Immune director Buetler reports initial holdings

AC Immune SA director Monika Buetler filed an initial statement of beneficial ownership, detailing existing share and option positions.

Rhea-AI Filing Summary

AC Immune SA director Monika Buetler filed an initial statement of beneficial ownership, detailing existing share and option positions. She reports direct ownership of 53,905 common shares, which includes 52,905 common shares underlying outstanding restricted share units. This filing does not show new buying or selling activity.

Buetler also holds several share options over AC Immune common shares with different exercise prices and maturities. These include options over 14,310 shares at an exercise price of 5.3100 that are fully vested and expire on December 9, 2031, and options over 56,204 shares at an exercise price of 3.1500 expiring on June 23, 2032. She further holds options over 39,823 shares at 2.1500 expiring June 23, 2033, and 15,501 shares at 4.2300 expiring June 30, 2034. Another option covers 46,392 shares at 1.8400 and will fully vest on June 17, 2026, with expiration on June 17, 2035. Together, these positions describe her current equity-based exposure to AC Immune, rather than recent market transactions.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider Buetler Monika

Role Director

Type	Security	Shares	Price	Value
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Common Shares	--	--	--

Holdings After Transaction: Share Option (right to buy) — 172,230 contracts (Direct); Common Shares — 53,905 shares (Direct)

Footnotes (3)

1. F1. Includes 52,905 common shares underlying outstanding restricted share units.
2. F2. The share option is fully vested.
3. F3. The share option will fully vest on June 17, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does AC Immune (ACIU) director Monika Buetler report in this Form 3?

Monika Buetler reports her existing ownership in AC Immune, including 53,905 common shares and multiple option grants over additional common shares. The Form 3 outlines her starting equity position as a director, not new purchases or sales.

How many AC Immune (ACIU) common shares does Monika Buetler directly own?

She directly owns 53,905 common shares of AC Immune. This figure includes 52,905 common shares underlying outstanding restricted share units, giving investors a view of both currently held shares and equity tied to compensation awards.

What option holdings over AC Immune (ACIU) shares does Monika Buetler disclose?

She discloses several share options over AC Immune common shares with different exercise prices and maturities, including grants at 5.3100, 3.1500, 2.1500, 4.2300, and 1.8400. These options provide potential future share ownership if exercised before their expiration dates.

Are Monika Buetler’s AC Immune (ACIU) options already vested?

Some of her options are already fully vested, while one grant will fully vest on June 17, 2026. Vested options can typically be exercised subject to plan terms, whereas unvested options become exercisable only after meeting vesting conditions.

Does this AC Immune (ACIU) Form 3 show insider buying or selling activity?

The Form 3 does not show new buying or selling activity. Instead, it lists Buetler’s existing common share and option holdings as she becomes a reporting insider, establishing a baseline for any future Form 4 transaction reports.

Why is Monika Buetler’s AC Immune (ACIU) Form 3 important for investors?

The Form 3 establishes Buetler’s initial ownership in AC Immune, including common shares, restricted share units, and options. This baseline helps investors later compare any Form 4 transactions against her previously disclosed equity position and gauge changes over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 12:35 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Buetler Monika

(Last) (First) (Middle)

EPFL INNOVATION PARK, BUILDING B

(Street)

LAUSANNE SWITZERLAND 1015

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
AC Immune SA [ ACIU ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	53,905(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	(2)	12/09/2031	Common Shares	14,310	$5.31	D
Share Option (right to buy)	(2)	06/23/2032	Common Shares	56,204	$3.15	D
Share Option (right to buy)	(2)	06/23/2033	Common Shares	39,823	$2.15	D
Share Option (right to buy)	(2)	06/30/2034	Common Shares	15,501	$4.23	D
Share Option (right to buy)	(3)	06/17/2035	Common Shares	46,392	$1.84	D

Explanation of Responses:

1. Includes 52,905 common shares underlying outstanding restricted share units.

2. The share option is fully vested.

3. The share option will fully vest on June 17, 2026.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Matthias Maurer, attorney-in-fact for Monika Buetler	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)